Advertisement

Medical Oncology

, Volume 27, Issue 3, pp 618–623 | Cite as

Bone marrow hyaluronan and reticulin in patients with malignant disorders

  • G. SundströmEmail author
  • M. Hultdin
  • A. Engström-Laurent
  • I. M. S. Dahl
Original Paper

Abstract

Myelofibrosis is commonly seen in patients with chronic myeloproliferative diseases and sometimes in myelodysplastic syndrome, acute leukaemia and lymphoproliferative diseases. The fibrotic process is evaluated by grading the amount of collagen deposited in the bone marrow interstitium. The established method to evaluate bone marrow fibrosis is staining for reticulin to visualise the collagen fibres. However, the extra cellular matrix does not only contain collagens but also other components, e.g. glycosaminoglycans of which hyaluronan is the most abundant. Hyaluronan is important for structural and cellular functions. Earlier studies have shown that there is a positive correlation between hyaluronan and reticulin staining in healthy volunteers and in patients with de novo acute myeloid leukaemia. In this study bone marrow biopsies from 43 patients with a malignant disease involving the bone marrow were compared with 18 patients with a malignant disease not involving the bone marrow. The intensity of hyaluronan grading was significantly higher in the patients with disease involving the bone marrow compared to the healthy controls but not compared to the patients without disease involving the bone marrow. The staining intensity of reticulin in the bone marrow was significantly higher in the patients with disease involving the bone marrow, compared to those without disease involving the bone marrow and to the controls. In all patients and the controls there was a correlation between hyaluronan and reticulin.

Keywords

Hyaluronan Reticulin Fibrosis Bone marrow Tumour Malignant disorder 

Notes

Acknowledgements

This study was supported by grants from the Lion’s Cancer Research Foundation at Umeå University. We are indebted to Professor Anders Wahlin for critical examination, good statistical advice from Björn Tavelin, skilful technical assistance from Berith Lundström and excellent secretarial help from Kerstin Rosenqvist.

References

  1. 1.
    Löfvenberg E, Wahlin A, Roos G, Öst Å. Reversal of myelofibrosis by hydroxyurea. Eur J Haematol. 1990;44:33–8.CrossRefPubMedGoogle Scholar
  2. 2.
    Reilly JT. Idiopathic myelofibrosis: pathogenesis, natural history and management. Blood Rev. 1997;11:233–42. doi: 10.1016/S0268-960X(97)90022-9.CrossRefPubMedGoogle Scholar
  3. 3.
    Harrison CN, Campel PJ, Buck G, Wheatley K, East CL, Bareford D, et al. United Kingdom Medical Research Council Primary Thrombocythemia 1 Study. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005;353:33–45. doi: 10.1056/NEJMoa043800.CrossRefPubMedGoogle Scholar
  4. 4.
    Maschek H, Georgii A, Katoutsi V, Werner M, Bandecar K, Kressel M-G, et al. Myelofibrosis in primary myelodysplastic syndromes: a retrospective study of 352 patients. Eur J Haematol. 1992;48:208–14.CrossRefPubMedGoogle Scholar
  5. 5.
    Marisavljevic D, Rolovic Z, Cemerikic V, Boskovic D, Colovic M. Myelofibrosis in primary myelodysplastic syndromes: clinical and biological significance. Med Oncol. 2004;21:325–31. doi: 10.1385/MO:21:4:325.CrossRefPubMedGoogle Scholar
  6. 6.
    Bouroncle BA, Wiseman BK, Doan CA. Leukemic reticuloendotheliosis. Blood. 1958;13:609–30.PubMedGoogle Scholar
  7. 7.
    Bouroncle BA. Thirty-five years in the progress of hairy cell leukaemia. Leuk Lymphoma. 1994;14(Suppl 1):1–12.PubMedGoogle Scholar
  8. 8.
    Quesada JR, Reuben J, Manning JT, et al. Alpha interferon for induction of remission in hairy-cell leukaemia. N Engl J Med. 1984;15:310.Google Scholar
  9. 9.
    Burke JS, Byrne GEJ, Rappaport H. Hairy cell leukaemia (leukemic reticuloendotheliosis). A clinical pathologic study of 21 patients. Cancer. 1974;33:1399. doi: 10.1002/1097-0142(197405)33:5<1399::AID-CNCR2820330526>3.0.CO;2-E.CrossRefPubMedGoogle Scholar
  10. 10.
    Manoharan A, Horsley R, Pitney WR. The reticulin content of bone marrow in acute leukaemia in adults. Br J Haematol. 1979;43:185–90. doi: 10.1111/j.1365-2141.1979.tb03740.x.CrossRefPubMedGoogle Scholar
  11. 11.
    Thiele J, Grashof K, Fischer R. Follow-up study on bone marrow reticulin fibrosis in AML. Anal Cell Pathol. 1991;3:225–31.PubMedGoogle Scholar
  12. 12.
    Islam A. Proposal for a classification of acute myeloid leukaemia based on plastic-embedded bone marrow biopsy sections. Leuk Res. 1993;17:421–7.CrossRefPubMedGoogle Scholar
  13. 13.
    Bauermeister DE. Quantitation of bone marrow reticulin—a normal range. Am J Clin Pathol. 1971;56:24–31.PubMedGoogle Scholar
  14. 14.
    Thiele J, Kvasnicka HM, Fachetti F, Franco V, van der Walt J, Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. 2005;90:1128–32.PubMedGoogle Scholar
  15. 15.
    Balazs EA, Laurent TC, Jeanloz RW. Nomenclature of hyaluronic acid. Biochem J. 1986;235:903.PubMedGoogle Scholar
  16. 16.
    Fraser JR, Laurent TC, Laurent UB. Hyaluronan. Its nature, distribution, functions and turnover. J Intern Med. 1997;242:27–33. doi: 10.1046/j.1365-2796.1997.00170.x.CrossRefPubMedGoogle Scholar
  17. 17.
    Toole BP. Hyaluronan in morphogenesis. J Intern Med. 1997;242:35. doi: 10.1046/j.1365-2796.1997.00171.x.CrossRefPubMedGoogle Scholar
  18. 18.
    Tammi M, Day A, Turley E. Hyaluronan and homeostasis: a balancing act. J Biol Chem. 2002;277:4581–4. doi: 10.1074/jbc.R100037200.CrossRefPubMedGoogle Scholar
  19. 19.
    Itano N, Zhuo L, Kimata K. Review article. Impact of the hyaluronan-rich tumour microenvironment on cancer initiation and progression. Cancer Sci. 2008;99:1720–5. doi: 10.1111/j.1349-7006.2008.00885.x.CrossRefPubMedGoogle Scholar
  20. 20.
    Tammi RH, Kultti A, Pirinen R, Kosma VM, Auvinen P, Tammi MI. Hyaluronan in human tumours: pathobiological and prognostic messages from cell-associated and stromal hyaluronan. Semin Cancer Biol. 2008;18:288–95.CrossRefPubMedGoogle Scholar
  21. 21.
    Sundström G, Löfvenberg E, Hassan I, Engström-Laurent A. Localisation and distribution of hyaluronan in normal bone marrow matrix: a novel method to evaluate impending fibrosis? Eur J Haematol. 2002;68:194–202. doi: 10.1034/j.1600-0609.2002.01617.x.CrossRefPubMedGoogle Scholar
  22. 22.
    Sundström G, Dahl IMS, Hultdin M, Lundström B, Wahlin A, Engsröm-Laurent A. Bone marrow hyaluronan distribution in patients with acute myeloid leukaemia. Med Oncol. 2005;22:71–8. doi: 10.1385/MO:22:1:071.CrossRefPubMedGoogle Scholar
  23. 23.
    Hultdin M, Sundström G, Wahlin A, Lundström B, Samuelsson J, Birgegård G, et al. Progression of bone marrow fibrosis in patients with essential thrombocythemia and polycythemia vera during anagrelide treatment. Med Oncol. 2007;24:63–70.CrossRefPubMedGoogle Scholar
  24. 24.
    Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposed revised criteria for the classification of acute myeloid leukaemia. A report of the French–American–British Cooperative Group. Ann Intern Med. 1985;103:620–5.PubMedGoogle Scholar
  25. 25.
    Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, et al. A revised European–American classification of lymphoid neoplasms. A proposal from the International Lymphoma Study Group. Blood. 1994;84:1361–92.PubMedGoogle Scholar
  26. 26.
    Putt FA. Manual of histological staining methods. New York: Wiley & Sons; 1972.Google Scholar
  27. 27.
    Tengblad A. Affinity chromatography on immobilized hyaluronate and its application to the isolation of hyaluronate binding proteins from cartilage. Biochim Biophys Acta. 1979;578:281–9.PubMedGoogle Scholar
  28. 28.
    Nilsson S, et al. Hyaluronan is synthesized by primitive haematopoietic cells, participates in their lodgement at the endosteum, following transplantation, and is involved in the regulation of their proliferation and differentiation in vitro. Blood. 2003;101:856–62.CrossRefPubMedGoogle Scholar
  29. 29.
    Toole BP. Hyaluronan–cell interactions in cancer and vascular disease. J Biol Chem. 2002;277:4593–6. doi: 10.1074/jbc.R100039200.CrossRefPubMedGoogle Scholar
  30. 30.
    Khaldoyanidi S. Directing stem cell homing. Cell Stem Cell. 2008;2(3):198–200. doi: 10.1016/j.stem.2008.02.012.CrossRefPubMedGoogle Scholar

Copyright information

© Humana Press Inc. 2009

Authors and Affiliations

  • G. Sundström
    • 1
    Email author
  • M. Hultdin
    • 2
  • A. Engström-Laurent
    • 3
  • I. M. S. Dahl
    • 4
  1. 1.Department of Oncology, Section of HaematologyNorrlands University HospitalUmeåSweden
  2. 2.Department of Medical Biosciences, PathologyUmeå UniversityUmeåSweden
  3. 3.Department of Public Health and Clinical MedicineUmeå UniversityUmeåSweden
  4. 4.Department of Medicine, Institute of Clinical MedicineUniversity of TromsöTromsöNorway

Personalised recommendations